Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy.

OBJECTIVE The aim of this study was to develop and validate a neuropathy sensory symptom scale, the Neuropathy Total Symptom Score-6 (NTSS-6), which evaluates individual neuropathy sensory symptoms in patients with diabetes mellitus (DM) and diabetic peripheral neuropathy (DPN) in clinical trials, with the intent of distinguishing a response to therapy. METHODS The NTSS-6 questionnaire was developed to evaluate the frequency and intensity of individual neuropathy sensory symptoms identified frequently by patients with DPN (ie, numbness and/or insensitivity; prickling and/or tingling sensation; burning sensation; aching pain and/or tightness; sharp, shooting, lancinating pain; and allodynia and/or hyperalgesia). The NTSS-6 was administered 8 times over a 1-year period to DPN patients. The NTSS-6's reliability (determined by internal consistency and test-retest reproducibility), construct validity, convergent validity, and minimally clinically important differences (MCIDs) were determined. RESULTS The NTSS-6 was administered to a total of 205 patients at 10 centers in the United States, Canada, Belgium, Germany, Hungary, Croatia, Slovenia, and the United Kingdom. Internal consistency was demonstrated at all 8 visits (Cronbach's alpha > 0.7). Test-retest reproducibility (intraclass correlation coefficient >0.9) was observed during the baseline period and at end point. Construct validity was demonstrated by statistically significant correlations between the NTSS-6 total score and the Neuropathy Symptoms and Change (NSC) score (r = 0.773-0.885, P < 0.001). Convergent validity was demonstrated by statistically significant correlations between the change in NTSS-6 total scores and the following: change in NSC scores (r = 0.519-0.708, P < 0.001); change in Neuropathy Impairment Score of the Lower Limbs and composite nerve function scores (r = 0.188-0.202, P < 0.007), and categories of the Clinical Global Impressions (r = 0.402, P < 0.001). The within- and between-groups MCIDs for the total NTSS-6 total scores were -1.26 and 0.97 points, respectively. The mean (SD) within-group MCID for all patients who improved on the Clinical Global Impression was -2.29 (3.4) points. CONCLUSIONS The NTSS-6 provided a valid assessment of neuropathy sensory symptoms in this sample of patients with DM and DPN, which suggests that it may be useful for symptom evaluation in clinical trials and practice. The NTSS-6 showed internal consistency, test-retest reliability, and construct validity. There was also convergent validity of the scores, indicating that the NTSS-6 may be a suitable questionnaire for clinical trials that evaluate symptoms of DPN in this well-defined patient population.

[1]  A. Boulton,et al.  A novel approach to the diagnosis and assessment of symptomatic diabetic neuropathy , 1989, Pain.

[2]  T. Larson,et al.  Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group. , 2000, Diabetes care.

[3]  A. Boulton,et al.  The Prevalence of Symptomatic, Diabetic Neuropathy in an Insulin-treated Population , 1985, Diabetes Care.

[4]  Gordon H Guyatt,et al.  Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.

[5]  E. C. Huskisson,et al.  Graphic representation of pain , 1976, Pain.

[6]  H. Fields,et al.  Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials , 2001, Journal of the Neurological Sciences.

[7]  J. O’Hare,et al.  Prevalence and forms of neuropathic morbidity in 800 diabetics , 1994, Irish journal of medical science.

[8]  P. Dyck,et al.  Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis , 1986, Neurology.

[9]  R. Hays,et al.  Development of a Health-Related Quality of Life Measure for Peripheral Neuropathy , 2000, Neurorehabilitation and neural repair.

[10]  M. Rowbotham,et al.  Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study , 2004, Pain.

[11]  W. J. Litchy,et al.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort , 1993, Neurology.

[12]  B. Galer,et al.  Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. , 2000, Diabetes research and clinical practice.

[13]  R. Melzack.  The McGill Pain Questionnaire: Major properties and scoring methods , 1975, PAIN.

[14]  M. Detke,et al.  Duloxetine vs. placebo in patients with painful diabetic neuropathy , 2005, Pain.

[15]  N. N. Available.  World medical association declaration of Helsinki , 2000, Chinese Journal of Integrative Medicine.

[16]  C. McHorney,et al.  Individual-patient monitoring in clinical practice: are available health status surveys adequate? , 1995, Quality of Life Research.

[17]  L. Bouter,et al.  Complaints of neuropathy related to the clinical and neurophysiological assessment of nerve function in patients with diabetes mellitus. , 1994, Diabetes research and clinical practice.

[18]  M. Hanefeld,et al.  Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. , 1999, Diabetes care.

[19]  S. Chia,et al.  Neuropathy in non-insulin-dependent diabetes mellitus. The significance of symptoms. , 1998, Scandinavian journal of primary health care.

[20]  M. Hanefeld,et al.  Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid , 1995, Diabetologia.

[21]  S. Eckstein.  Ethical principles for medical research involving human subjects. , 2001, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[22]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[23]  S. Benbow,et al.  Painful diabetic neuropathy , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[24]  C. Cleeland,et al.  Validity of the Brief Pain Inventory for Use in Documenting the Outcomes of Patients With Noncancer Pain , 2004, The Clinical journal of pain.

[25]  M. Harris,et al.  Symptoms of Sensory Neuropathy in Adults with NIDDM in the U.S. Population , 1993, Diabetes Care.

[26]  Karen L. Price,et al.  Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. , 2005, Clinical therapeutics.

[27]  B. Perkins,et al.  Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. , 2002, Diabetes care.

[28]  M. Rowbotham,et al.  The Lidocaine Patch 5% Effectively Treats All Neuropathic Pain Qualities: Results of a Randomized, Double-Blind, Vehicle-Controlled, 3-Week Efficacy Study With Use of the Neuropathic Pain Scale , 2002, The Clinical journal of pain.

[29]  D. Cucinotta,et al.  A Multicenter Study on the Prevalence of Diabetic Neuropathy in Italy , 1997, Diabetes Care.

[30]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[31]  H. Arnqvist,et al.  Painful Polyneuropathy in Patients With and Without Diabetes: Clinical, Neurophysiologic, and Quantitative Sensory Characteristics , 2002, The Clinical journal of pain.

[32]  L. Melton,et al.  Erratum: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study (Neurology (1993) 43 (817-824)) , 1993 .

[33]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[34]  A. Beydoun,et al.  Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: a Randomized Controlled Trial , 1999 .

[35]  P. Sönksen,et al.  A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population , 1993, Diabetologia.

[36]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[37]  J. Stephenson,et al.  Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study , 1996, Diabetologia.

[38]  K N Lohr,et al.  Evaluating quality-of-life and health status instruments: development of scientific review criteria. , 1996, Clinical therapeutics.

[39]  M B Brown,et al.  A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy , 1994, Diabetes Care.

[40]  L. Markson,et al.  Quality-of-life questionnaire for patients taking antihypertensive medication. , 1999, Clinical therapeutics.

[41]  P. Dyck.  Detection, characterization, and staging of polyneuropathy: Assessed in diabetics , 1988, Muscle & nerve.

[42]  T. Wagner,et al.  Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL) , 1999, Urology.

[43]  E. Bass,et al.  Epidemiological Correlates of Diabetic Neuropathy: Report From Pittsburgh Epidemiology of Diabetes Complications Study , 1989, Diabetes.

[44]  Peter J Dyck,et al.  Electronic Case-Report Forms of Symptoms and Impairments of Peripheral Neuropathy , 2002, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[45]  R. Kikkawa,et al.  Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. , 2001, Diabetes care.

[46]  P. O'Brien,et al.  The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With α-Lipoic Acid , 2003 .

[47]  D. Cornblath,et al.  Total neuropathy score , 1999, Neurology.

[48]  W. Litchy,et al.  Variables influencing neuropathic endpoints , 1995, Neurology.

[49]  J. Arezzo,et al.  Diabetic somatic neuropathies. , 2004, Diabetes care.

[50]  M. Lacerenza,et al.  Pain in diabetic neuropathy case study: whole patient management , 2004, European journal of neurology.

[51]  W. Litchy,et al.  Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort , 1997, Neurology.

[52]  S. Kulseng‐Hanssen,et al.  The development of a questionnaire to measure the severity of symptoms and the quality of life before and after surgery for stress incontinence , 2003, BJOG : an international journal of obstetrics and gynaecology.